US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.4720

-0.0267-5.35%

Volume:68.94K

Turnover:33.05K

Market Cap:4.64M

PE:-0.03

High:0.4986

Open:0.4974

Low:0.4700

Close:0.4987

52wk High:49.25

52wk Low:0.4600

Shares:9.83M

Float Shares:9.82M

Volume Ratio:0.90

T/O Rate:0.70%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-17.6157

EPS(LYR):-371.2241

ROE:-161.86%

ROA:-70.14%

PB:0.49

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients

Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors

Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4

THOMSON REUTERS

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

Propanc Biopharma Accelerates Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors

Propanc Biopharma - Prp Shows Reduced Metastatic Burden in Liver and Peritoneum

THOMSON REUTERS

Propanc Biopharma - Prp Extends Median Overall Survival by over 2.5-Fold in Animal Models

THOMSON REUTERS

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% TUMOR Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

THOMSON REUTERS

Propanc Biopharma - to Accelerate Phase 1B First-in-Human Study in Pancreatic Cancer

THOMSON REUTERS

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

THOMSON REUTERS

Propanc Biopharma Files Draft Information Statement on Restricted Stock Issuances

Propanc Biopharma Names Carlo Campiciano to Board After Van Broekhoven Retirement

Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b Trial Delivery

Propanc Biopharma - Mou to Support Phase 1B First-in-human Trial for Propanc's Prp

THOMSON REUTERS

Propanc Biopharma Signs Mou with Avance Clinical Pty Ltd

THOMSON REUTERS

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

THOMSON REUTERS

Propanc CEO visits European manufacturer ahead of drug production plan

Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PPCB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.472,"timestamp":1791473002007,"preClose":0.4987,"halted":0,"volume":68942,"delay":0,"changeRate":-0.05353920192500502,"floatShares":9818240,"shares":9831100,"eps":-17.61573,"marketStatus":"Trading","change":-0.0267,"latestTime":"10-08 11:23:36 EDT","open":0.4974,"high":0.4986,"low":0.47,"amount":33045.5621022,"amplitude":0.057349,"askPrice":0.5,"askSize":47,"bidPrice":0.45,"bidSize":115,"shortable":3,"etf":0,"ttmEps":-17.61573,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.4987,"preHourTrading":{"tag":"盘前","latestPrice":0.4815,"preClose":0.4987,"latestTime":"09:26 EDT","volume":9958,"amount":4921.1823583,"timestamp":1791465995075,"change":-0.0172,"changeRate":-0.03449,"amplitude":0.04612},"postHourTrading":{"tag":"盘后","latestPrice":0.487,"preClose":0.4987,"latestTime":"19:44 EDT","volume":19045,"amount":9750.8857,"timestamp":1791416649621,"change":-0.0117,"changeRate":-0.023461,"amplitude":0.13455},"volumeRatio":0.895475},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":9818240,"roa":"-70.14%","roe":"-161.86%","lyrEps":-371.224075,"volumeRatio":0.895475,"shares":9831100,"dividePrice":0,"high":0.4986,"amplitude":0.057349,"preClose":0.4987,"low":0.47,"week52Low":0.46,"pbRate":"0.49","week52High":49.25,"institutionHeld":0,"latestPrice":0.472,"committee":0.419753,"eps":-17.61573,"divideRate":0,"volume":68942,"delay":0,"ttmEps":-17.61573,"open":0.4974,"prevYearClose":13.415,"prevWeekClose":0.5075,"prevMonthClose":0.494,"prevQuarterClose":0.494,"fiveDayClose":0.501,"twentyDayClose":0.9428,"sixtyDayClose":1.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-10-07","current":-0.026791,"percent":0.384083,"low":-1.336323,"twenty":-0.242645,"median":-0.125949,"eighty":-0.04348,"high":-0.023125,"avg":-0.177844,"sd":0.185862,"marketCap":3110477},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767},{"date":"2026-09-04","current":-0.12657,"twenty":-0.273833,"median":-0.12719,"eighty":-0.041245,"marketCap":2323938},{"date":"2026-09-11","current":-0.11699,"twenty":-0.269509,"median":-0.12657,"eighty":-0.041322,"marketCap":2148048},{"date":"2026-09-18","current":-0.078175,"twenty":-0.266901,"median":-0.125329,"eighty":-0.041661,"marketCap":1435373},{"date":"2026-09-25","current":-0.074676,"twenty":-0.254295,"median":-0.123158,"eighty":-0.042494,"marketCap":1371123},{"date":"2026-10-02","current":-0.168157,"twenty":-0.244862,"median":-0.125329,"eighty":-0.042786,"marketCap":3171889},{"date":"2026-10-07","current":-0.164901,"twenty":-0.242645,"median":-0.125949,"eighty":-0.04348,"marketCap":3110477}],"updateTime":1791473015877},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661261985","title":"Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261985","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661261985?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:01","pubTimestamp":1787306484,"startTime":"0","endTime":"0","summary":"Propanc Biopharma issues 3.5 million restricted shares to executives, directors, service providersPropanc Biopharma board resolutions dated July 24, 2026 were executed via majority shareholder written","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL85S1XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","MEDX","PPCB","NVIB","IDNA","BK4139","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446786","title":"Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446786","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446786?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:32","pubTimestamp":1787056337,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans first-in-human Phase 1b trial of PRP in up to 40 advanced solid tumor patientsPropanc Biopharma began finalizing plans for a first-in-human Phase 1b study of PRP in up to 40 ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL7Y8rDm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","BCDF","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","BK4588","LU0314104364.USD","BK4585","IE00BKPKM429.USD","PPCB","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BQXX3C00.GBP","BK4112","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658397776","title":"Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658397776","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658397776?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:46","pubTimestamp":1786538783,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans Phase 1b study of PRP proenzyme therapy in advanced solid tumorsPropanc outlined PRP, a once-weekly IV combination of trypsinogen and chymotrypsinogen, as a differentiation-bas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1QJjyz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658779079","title":"Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2658779079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658779079?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:36","pubTimestamp":1786538212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163740","title":"Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163740?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:51","pubTimestamp":1786024283,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma, one of th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363163","title":"Propanc Biopharma Accelerates Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363163","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363163?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:36","pubTimestamp":1786019818,"startTime":"0","endTime":"0","summary":"Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumorsPropanc Biopharma on Aug. 6, 2026 flagged new preclinical, early translational PRP data in pancreatic cancer mod","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL117tCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631800","title":"Propanc Biopharma - Prp Shows Reduced Metastatic Burden in Liver and Peritoneum","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631800?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631388","title":"Propanc Biopharma - Prp Extends Median Overall Survival by over 2.5-Fold in Animal Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631388?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657386631","title":"Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% TUMOR Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2657386631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657386631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657313516","title":"Propanc Biopharma - to Accelerate Phase 1B First-in-Human Study in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657313516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657313516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657440135","title":"Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2657440135","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657440135?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:30","pubTimestamp":1785933000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA9YSQLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510441","title":"Propanc Biopharma Files Draft Information Statement on Restricted Stock Issuances","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510441","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510441?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:00","pubTimestamp":1785924059,"startTime":"0","endTime":"0","summary":"Propanc Biopharma files draft information statement on restricted stock issuancesPropanc Biopharma shareholders authorized new restricted common stock issuances totaling 3.5 million shares for officer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4bhhmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651486063","title":"Propanc Biopharma Names Carlo Campiciano to Board After Van Broekhoven Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2651486063","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651486063?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:02","pubTimestamp":1784059336,"startTime":"0","endTime":"0","summary":"Propanc Biopharma names Carlo Campiciano to board after Van Broekhoven retirementPropanc Biopharma reported a board change effective July 8, 2026, with director Annie Van Broekhoven retiring and stepp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLX4K6t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AHE.AU","PPCB","BK7094","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649980618","title":"Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b Trial Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980618","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980618?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:33","pubTimestamp":1783427581,"startTime":"0","endTime":"0","summary":"Propanc Biopharma signs MOU with Avance Clinical for PRP Phase 1b trial deliveryPropanc Biopharma signed an MOU with Avance Clinical to support clinical delivery of its Phase 1b first-in-human trial o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL7HSY8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4585","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","PPCB","BK4139","IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","BCDF","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987716","title":"Propanc Biopharma - Mou to Support Phase 1B First-in-human Trial for Propanc's Prp","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987716?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA4WFN1F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649877469","title":"Propanc Biopharma Signs Mou with Avance Clinical Pty Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2649877469","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649877469?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA4WFN1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648507485","title":"Propanc Biopharma Initiates $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648507485","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648507485?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA8RDFQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643768348","title":"Propanc CEO visits European manufacturer ahead of drug production plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643768348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643768348?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:41","pubTimestamp":1781617271,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that CEO James Nathanielsz toured a European contract development and manufacturing organization’s facility in p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-ceo-visits-european-manufacturer-ahead-of-drug-production-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-ceo-visits-european-manufacturer-ahead-of-drug-production-plan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPV","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757305","title":"Propanc Biopharma CEO tours European CDMO GMP facility ahead of PRP production for Phase 1b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757305","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757305?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:45","pubTimestamp":1781613920,"startTime":"0","endTime":"0","summary":"Propanc Biopharma CEO James Nathanielsz toured a European CDMO’s GMP facility to prepare for PRP production tied to its Phase 1b first-in-human study.Propanc aligned project timelines with the manufacturer, targeting preproduction in August 2026, an engineering run in October 2026, GMP manufacture from December 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL33tlpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","PPCB","SG9999014013.SGD","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}]}}